Inalways
Mediera Corporation manufactures electronic and power supply components in Taiwan. It is also involved in the medical biotechnology business. The company offers medicines, health food, and medical device, etc. Mediera Corporation was founded in 1967 and is based in New Taipei City, Taiwan.
Inalways (5398) - Net Assets
Latest net assets as of September 2025: NT$537.75 Million TWD
Based on the latest financial reports, Inalways (5398) has net assets worth NT$537.75 Million TWD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$630.75 Million) and total liabilities (NT$93.01 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$537.75 Million |
| % of Total Assets | 85.25% |
| Annual Growth Rate | 7.23% |
| 5-Year Change | -3.35% |
| 10-Year Change | N/A |
| Growth Volatility | 34.68 |
Inalways - Net Assets Trend (2015–2024)
This chart illustrates how Inalways's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Inalways (2015–2024)
The table below shows the annual net assets of Inalways from 2015 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$547.85 Million | +8.57% |
| 2023-12-31 | NT$504.59 Million | -6.47% |
| 2022-12-31 | NT$539.52 Million | -4.16% |
| 2021-12-31 | NT$562.96 Million | -0.68% |
| 2020-12-31 | NT$566.84 Million | +1.09% |
| 2019-12-31 | NT$560.74 Million | +5.70% |
| 2018-12-31 | NT$530.49 Million | -15.39% |
| 2017-12-31 | NT$627.01 Million | +3.51% |
| 2016-12-31 | NT$605.72 Million | +107.28% |
| 2015-12-31 | NT$292.23 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Inalways's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 911300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | NT$586.10 Million | 106.98% |
| Total Equity | NT$547.85 Million | 100.00% |
Inalways Competitors by Market Cap
The table below lists competitors of Inalways ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Fima Corporation Bhd
KLSE:3107
|
$22.25 Million |
|
Cansortium Inc
OTCQB:CNTMF
|
$22.25 Million |
|
K Auction Inc.
KQ:102370
|
$22.25 Million |
|
Habco Trans Maritima
JK:HATM
|
$22.27 Million |
|
Singbao International Co Ltd
TWO:6130
|
$22.23 Million |
|
Nido Education Ltd
AU:NDO
|
$22.23 Million |
|
PERFORMANCE SHIPP.
F:DS2
|
$22.23 Million |
|
VMCAF
OTCMKTS:VMCAF
|
$22.22 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Inalways's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 504,592,000 to 547,853,000, a change of 43,261,000 (8.6%).
- Net income of 10,435,000 contributed positively to equity growth.
- Other factors increased equity by 32,826,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$10.44 Million | +1.9% |
| Other Changes | NT$32.83 Million | +5.99% |
| Total Change | NT$- | 8.57% |
Book Value vs Market Value Analysis
This analysis compares Inalways's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.92x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.69x to 1.92x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | NT$12.55 | NT$21.25 | x |
| 2018-12-31 | NT$10.72 | NT$21.25 | x |
| 2019-12-31 | NT$11.34 | NT$21.25 | x |
| 2020-12-31 | NT$11.46 | NT$21.25 | x |
| 2021-12-31 | NT$11.38 | NT$21.25 | x |
| 2022-12-31 | NT$10.91 | NT$21.25 | x |
| 2023-12-31 | NT$10.20 | NT$21.25 | x |
| 2024-12-31 | NT$11.08 | NT$21.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Inalways utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.90%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.38%
- • Asset Turnover: 0.37x
- • Equity Multiplier: 1.19x
- Recent ROE (1.90%) is above the historical average (-3.98%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -37.13% | -53.68% | 0.59x | 1.17x | NT$-137.73 Million |
| 2016 | 1.48% | 2.68% | 0.43x | 1.27x | NT$-51.63 Million |
| 2017 | 2.88% | 3.31% | 0.70x | 1.24x | NT$-44.66 Million |
| 2018 | -11.71% | -11.69% | 0.84x | 1.19x | NT$-115.19 Million |
| 2019 | 4.52% | 5.85% | 0.65x | 1.19x | NT$-30.75 Million |
| 2020 | 2.94% | 4.53% | 0.57x | 1.14x | NT$-40.02 Million |
| 2021 | 2.88% | 4.61% | 0.54x | 1.15x | NT$-40.08 Million |
| 2022 | -1.26% | -2.64% | 0.42x | 1.13x | NT$-60.74 Million |
| 2023 | -6.30% | -16.49% | 0.35x | 1.10x | NT$-82.27 Million |
| 2024 | 1.90% | 4.38% | 0.37x | 1.19x | NT$-44.35 Million |
Industry Comparison
This section compares Inalways's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,317,013,700
- Average return on equity (ROE) among peers: 4.53%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Inalways (5398) | NT$537.75 Million | -37.13% | 0.17x | $22.24 Million |
| Grape King Bio Ltd (1707) | $2.08 Billion | 18.27% | 0.54x | $415.70 Million |
| Standard Chemical & Pharmaceutical Co Ltd (1720) | $4.20 Billion | 8.11% | 0.48x | $159.99 Million |
| Maywufa Co Ltd (1731) | $1.41 Billion | 2.15% | 1.10x | $41.61 Million |
| Allied Biotech Corporation (1780) | $1.08 Billion | 1.21% | 1.26x | $48.27 Million |
| ScinoPharm Taiwan Ltd (1789) | $10.36 Billion | 2.77% | 0.13x | $179.96 Million |
| GeneFerm Biotechnology Co Ltd (1796) | $396.19 Million | 1.14% | 1.48x | $23.77 Million |
| Easywell Biomedicals Inc. (1799) | $623.80 Million | -23.22% | 0.95x | $82.61 Million |
| LIWANLI Innovation Co Ltd (3054) | $897.52 Million | 5.08% | 0.06x | $51.25 Million |
| YungShin Global Holding Corp (3705) | $5.90 Billion | 12.21% | 0.47x | $295.98 Million |
| TTY Biopharm Co Ltd (4105) | $6.23 Billion | 17.56% | 0.54x | $484.94 Million |